Company news

Lantern Pharma Inc. news in 2026

Lantern Pharma Inc.'s news releases, calls and decks from 2026, newest first.

View company

Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 15th, 2026

October 8, 2026

Lantern Pharma Receives Taiwan Approvals to Open Next Stage of Phase 2 HARMONIC™ Trial of LP-300 in Never-Smoker, EGFR-Mutant NSCLC

October 7, 2026

Lantern Pharma Inc. Announces Closing of up to $8 Million Registered Direct Offering

September 30, 2026

Lantern Pharma Inc. Announces up to $8 Million Registered Direct Offering

September 29, 2026

Open-Medicine AI: Lantern Pharma to Present the Agentic AI Drug Development Market, User Needs, Development Roadmap, Platform Economics, and Benchmarks, Today at 12: 30 PM ET

September 23, 2026

Lantern Pharma Secures USPTO Notice of Allowance for LP‑284 Treatment Patent in Aggressive B‑Cell Lymphomas

September 22, 2026

Lantern Pharma to Present Open-Medicine AI — a Multi-Agentic Platform for End-to-End Therapeutic Development — Business Model, Roadmap, and Value Proposition on September 23

September 17, 2026

Lantern Pharma Reports Second Quarter 2026 Financial Results and Provides Business Update

August 14, 2026

Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9: 00 a.m. ET

August 7, 2026

Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine

August 3, 2026

Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer

July 28, 2026

Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers

July 23, 2026

Lantern Pharma Launches ZetaOmics™ — an Autonomous, Intelligent "Computational Biologist" That Brings Expert-Grade Bioinformatics, Biostatistics & Reasoning to Every Cancer

July 8, 2026

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer

June 2, 2026

Lantern Pharma Announces Successful Outcome of FDA Type C Meeting Request for HARMONIC™ Phase 2 Trial of LP-300 in Never-Smokers with NSCLC

May 18, 2026

Lantern Pharma Reports First Quarter 2026 Financial Results and Provides Business Updates

May 15, 2026

Lantern Pharma Inc. Announces Closing of up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 14, 2026

Lantern Pharma Inc. Announces up to $9.25 Million Registered Direct Offering with Existing Holders and a Single Institutional Investor

May 12, 2026

Lantern Pharma to Report First Quarter 2026 Operating & Financial Results on May 15th, 2026

May 11, 2026

Lantern Pharma Unveils Roadmap for withZeta.ai — Industry-First, Multi-Agentic Co-Scientist Featuring Swarm Intelligence and Computational Biology Toolkit with the Launch of ZetaSwarm™ and ZetaOmics™

May 7, 2026

Lantern Pharma’s predictBBB.ai Evolves Into a Real-Time Large Quantitative Model (LQM) for Precision Molecular Intelligence — Comprehensive Small Molecule Characterization & Development Analytics Available as a Web Service to Drug Developers Globally

April 29, 2026

Lantern Pharma to Debut Public Demonstration of withZeta.ai - A Platform to Conquer Rare Cancers on April 30 Following AACR 2026 Scientific Debut

April 24, 2026

Emerging Data for Lantern Pharma’s Investigational Drug LP-300 Demonstrates 8.3-Month Median Progression-Free Survival in Patients with EGFR L858R Lung Cancer After Targeted Therapy Failure — With No Added Toxicity

April 20, 2026

Lantern Pharma Launches withZeta.ai — the World’s First Multi-Agentic A.I. Co-Scientist for Rare Cancer Drug Discovery & Development — Subscriptions Now Open; Debut Events at Nasdaq MarketSite on 4/16 and at AACR 2026 from 4/17 to 4/22

April 13, 2026

Lantern Pharma Invites Investors, Analysts & Shareholders to Experience the Future of Drug Discovery via a Live Demo of withZeta.ai — the World's First Multi-Agentic Co-Scientist for Rare Cancers — 8: 30 AM Eastern, April 9, 2026

April 1, 2026

Lantern Pharma Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

March 29, 2026

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

March 26, 2026

Lantern Pharma and Starlight Therapeutics Announce FDA Clearance of IND for a Planned Phase 1 Pediatric CNS Cancer Trial of STAR-001

March 26, 2026

Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March 30th, 2026 at 4: 30 p.m. ET

March 22, 2026

Lantern Pharma to Present at the 7th Glioblastoma Drug Development Summit in Boston on February 17-19, 2026

February 10, 2026

Lantern Pharma's LP-284 Receives FDA Orphan Drug Designation for Soft Tissue Sarcomas

January 20, 2026

Lantern Pharma Announces Establishing an A.I. Center of Excellence in India to Industrialize the RADR® Platform and Accelerate Global Development Opportunities with BioPharma Companies

January 12, 2026

Calls in 2026

Decks in 2026